Please login to the form below

Not currently logged in
Email:
Password:

evolocumab

This page shows the latest evolocumab news and features for those working in and with pharma, biotech and healthcare.

Novartis picks up inclisiran after completion of MedCo acquisition

Novartis picks up inclisiran after completion of MedCo acquisition

This dosing schedule means that MedCo’s drug could pose a major challenge to established drugs in the class, including Amgen’s Repatha (evolocumab) and Sanofi/Regeneron’s Praluent (alirocumab).

Latest news

More from news
Approximately 11 fully matching, plus 66 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...
Pills
Tackling antimicrobial resistance on multiple fronts
An urgent change of direction is needed in how we respond to AMR...

Infographics